2024
1) Kraus FM, Traut A, Nilius G, Volmerig J, Koziorowski A, Stöver I, Grabellus F, Stahl M, Christoph DC (2024): Pulmonary adenocarcinoma with enteric differentiation (PAED) without TTF-1 expression is a very rare subtype with limited treatment options and poor prognosis. Oncology in Druck.

2) Ferentinos K, Traut A, Gubelt L, Nilius G, Czyborra PB, Nusch A, Langer W, Nückel H, Hannig CV, Stahl M, Christoph DC (2024): Effectiveness and Safety of Docetaxel in Combination with Nintedanib or Ramucirumab Following Chemoimmunotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer. J Oncol Res Ther 9: 10232. DOI: 10.29011/2574-710X.10232.

3) Kraus FM, Traut A, Gubelt L, Nilius G, Volmerig J, Koziorowski, Stöver I, Grabellus F, Stahl, M, Christoph DC (2024) Comparison of Single Agent Check-Point Inhibitors as First-Line Treatment in NSCLC Patients with High PD-L1-Expression. J Oncol Res Ther 9: 10228.

4) Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N (2024): Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R. ESMO Open 9(6):103464.

5) Neal J, Pavlakis N, Kim S-W, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin X, Palmero R, Antic V, Chun E, Edubilli TR, Lin Y-C, Huseni M, Ballinger M, Graupner V, Curran D, Vervaet P, Newsom-Davis T (2024): CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol 42(20):2393-2403.

2023
1) Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He H, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators (2023): SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Ann Oncol 35(1):66-76.

2) Borchert S, Mathilakathu A, Nath A, Wessolly M, Mairinger E, Kreidt D, Steinborn J, Walter RFH, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Mairinger FD (2023). Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model. Int J Mol Sci. 24(15):12426.
3) Stahl MK, Ertl SW, Engelmeyer P, Heuer HC, Christoph DC (2023): Impact of Geriatric Assessment on the Tolerability of Combination Chemotherapy in Older Patients with Advanced Cancer: A Matched-Pair Analysis. Oncol Res Treat. 46(3):100-105.

2022
1) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B (2022): Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study. J Thorac Oncol. 18:181-193

2) Zhang Z, Xie S, Cai W, Hong ZN, Yang C, Lin Y, Zhu J, Lin Z, Christoph DC, Bohnenberger H, Kepka L, Brueckl WM, Van Houtte P, Kang M, Lin J (2022): A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer. Transl Lung Cancer Res. 11(1):75-86.

2021
1) Mathilakathu A, Borchert S, Wessolly M, Mairinger E, Beckert H, Steinborn J, Hager T, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Schmid KW, Walter RFH, Brcic L, Mairinger FD (2021): Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study. Transl Lung Cancer Res 10(7):3030-3042.

2) Metzenmacher M, Kopp HG, Griesinger F, Reinmuth N, Sebastian M, Serke M, Waller CF, Thomas M, Eggert J, Schmid-Bindert G, Hoiczyk M, Christoph DC, Kimmich M, Deuß B, Seifert S, Held S, Schuler M, Herold T, Breitenbuecher F, Eberhardt WEE (2021): A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer. Ther Adv Med Oncol. 13:1758835921996506.

3) Zeuschner P, Hölters S, Stöckle M, Seliger B, Mueller A, Bachmann HS, Grünwald V, Christoph DC, Stenzl A, Grimm MO, Brüning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-Rüd I, Staehler M, Junker K (2021): Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study). Cancers (Basel) 13(11):2594.
4) Brcic L, Mathilakathu A, Walter RFH, Wessolly M, Mairinger E, Beckert H, Kreidt D, Steinborn J, Hager T, Christoph DC, Kollmeier J, Mairinger T, Wohlschlaeger J, Schmid KW, Borchert S, Mairinger FD (2021): Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity. Cancers (Basel) 13(8):1761.

5) Ferdinandus J, Metzenmacher M, Kessler L, Umutlu L, Aigner C, Karl KO, Grünwald V, Eberhardt W, Fendler WP, Herrmann K, Faehling M, Christoph DC (2021): Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. J Immunother Cancer 9(3):e002262.

6) Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, Gütz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F. (2021): Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther Adv Med Oncol. 13:1758835920980558.

Abstracts und Präsentationen auf Konferenzen:

2024
1) Shah R, Reck M, Grohe C, Christoph DC, Buchmeier EL, Saalfeld FC, Frost N, Kopp H-G, Faehling M, Griesinger F, Roeper J, Hoffknecht P, Kuon J, Luan J, Chesi P, Christopoulos P, Thomas M (2024): Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. J Clin Oncol 42, 2024 (suppl 16; abstr 8085). Posterpräsentation auf der Jahrestagung der American Society of Clinical Oncology.

2) Hautzel H, Metzenmacher M, Bölükbas S, Volmerig J, Nilius G, Kersting D, Moka D, Herrmann K, Christoph D (2024): Tumorvolumetrische Parameter MTV und TLG zur Prädiktion von progressionsfreiem und Gesamt-Überleben beim nicht-resektablen Malignen Mesotheliom unter Doppelimmuntherapie mit Ipilimumab und Nivolumab: Was kann die baseline FDG PET/CT leisten? NuclearMedicine 63 (2), V06. Vortrag auf dem Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin.

3) Christoph D, Metzenmacher M, Bölükbas S, Volmerig J, Nilius G, Moka D, Hautzel H (2024): PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma better than CT. Oncol Res Treat. Volume 47 (Supplement 1), P756. Posterpräsentation auf dem 36. Deutschen Krebskongress.

4) Karthaus M, Christoph D, Lux MP, Hofheinz R-D, Jordan K (2024): Bewertung des Nutzens von NEPA (fixe Kombination von Netupitant/Palonosetron) zur Vorbeugung von durch Chemotherapie ausgelöster Übelkeit und Erbrechen (CINV) bei Patienten mit erhöhtem Emesisrisiko, die eine moderat emetogene Chemotherapie erhalten. Oncol Res Treat. Volume 47 (Supplement 1), P445. Posterpräsentation auf dem 36. Deutschen Krebskongress.

5) Reitnauer L, Evers G, Christoph D, Brückl W, Wiesweg M, Glanemann F, Webendörfer M, Kropf-Sanchen C, Acker F, Schütte W, Hoffknecht P, Kerkhoff A, Mohr M, Lenz G, Frost N, Overbeck T, Sebastian M, Bleckmann A (2024): Recurrence of locally advanced NSCLC after radiochemotherapy and consolidative Durvalumab – A german multicenter retrospective analysis. Oncol Res Treat. Volume 47 (Supplement 1), P947. Posterpräsentation auf dem 36. Deutschen Krebskongress.

6) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph DC (2024): Addressing systemic first line therapy of elderly lung cancer patients is critical. Oncol Res Treat. Volume 47 (Supplement 1), P755. Posterpräsentation auf dem 36. Deutschen Krebskongress.

2023
1) Christoph DCCC, Metzenmacher M, Bölükbas S, Volmerig4 J, Nilius G, Moka D, Hautzel H (2023): PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT. Ann Oncol Volume 34 (Supplement 2): S1135-S1144, 2196P. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

2) Kuon JB, Blasi M, Kokowski K, Faehling4 M, Schuette W, Christoph DCC, Kimmich M, Engel-Riedel W, Fischer JR, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum Büschenfelde C, Griesinger F, Schneider M, Behnisch R, Stenzinger A, Christopoulos P, Thomas M (2023): DURATION: A multicenter randomized phase II trial investigating sequential mono- (mCTX) or doublet-chemotherapy (dCTX) followed by durvalumab (D) in older or frail patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol Volume 34 (Supplement 2): S755-S851, 1442P Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

3) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph DCCC (2023): Challenge of systemic first-line treatment of elderly lung cancer patients. Ann Oncol Volume 34 (Supplement 2): S755-S851, 1483P. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

4) Evers G, Reitnauer LE, Christoph DCCC, Brueckl WM, Wiesweg M, Glanemann F, Webendoerfer M, Kropf C, Acker F, Hund A, Schütte W, Hoffknecht P, Kerkhoff A, Mohr M, Lenz G, Frost N, Overbeck TR, Sebastian M, Bleckmann A (2023): Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab. Ann Oncol Volume 34 (Supplement 2): S746-S754, 1300P. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

5) Karthaus M, Christoph DC, Lux MP, Hofheinz RD, Jordan K (2023): Assessing the Benet of NEPA (Fixed Combination of Netupitant/Palonosetron) for preventing Chemotherapyinduced Nausea and Vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P724. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

6) Ferentinos K, Volmerig J, Nilius G, Jaeger B, Koziorowski A, Stoever I, Christoph D (2023): Systemic first line treatment of elderly patients with lung cancer: proper choice is difficult. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P453. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

7) Reitnauer L, Evers G, Christoph D, Brückl W, Wiesweg M, Glanemann F, Webendörfer M, Kropf-Sanchen C, Acker F, Schütte W, Hoff¬knecht P, Kerkho¬ A, Mohr M, Lenz G, Frost N, Overbeck T, Sebastian M, Bleckmann A (2023): Relapse after radiochemotherapy and consolidative Durvalumab in Stage III NSCLC – a retrospective analysis in a real-world setting. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P451. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

8) Christoph D, Metzenmacher M, Bölükbas S, Volmerig J, Nilius G, Moka D, Hautzel H (2023): PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT. Oncol Res and Treat 2023, Volume 46 (Supplement 5), P446. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

9) Peters S, Christoph DC, Field JK, Fietkau R, Filippi AR, Garassino M, Garrido P, McDonald F, Mornex F, Markman B, Solomon BJ, Anand S, Chander P, Qiao Y, Girard N (2023): Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFRMutated NSCLC (PACIFIC-R) J Thorac Oncol Volume 18 Issue 11 (Supplement), OA17.03. Vortrag auf der World Conference on Lung Cancer 2023.

10) Neal J, Pavlakis N, Kim S-W, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin A, Palmero R, Antic V, Chun E, Rao Edubilli T, Lin Y-C, Huseni M, Scheffold C, Vervaet P, Newsom-Davis T (2023): CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. Journal of Thoracic Oncology, Volume 18 Issue 4, S39 – S40. Vortrag auf der European Lung Cancer Conference 2023.

2022
1) Girard N, Christoph DCC, Garassino MC, McDonald F, Mornex F, Field JK, Fietkau R, Garrido Lopez P, Haakensen VD, Siva S, Van den Heuvel M, Bar J, Chouaid C, Vercauter P, Chander P, Licour M, Anand S, de Lima ARMD, Filippi ARR (2022): Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III non-small-cell lung cancer (NSCLC): interim analysis from the PACIFIC-R study. Ann Oncol Volume 16 (Supplement 1), O580. Posterpräsentation at the European Society of Medical Oncology Immuno-Oncology Congress 2022.

2) Galuba J, Stöver I, Koziorowski A, Bölükbas S, Nilius G, Christoph D (2022): Safety and efficacy of simultaneously performed radiotherapy in patients with small-cell lung cancer undergoing atezolizumab treatment. Oncol Res Treat. Volume 45 (Supplement 3), P606. Posterpräsentation auf dem 35. Deutschen Krebskongress.

3) Wessolly M, Mathilakathu A, Mairinger E, Nath A, Beckert H, Kreidt D, Klopp N, Hegedüs B, Steinborn J, Hager T, Walter RFH, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Borchert S, Schmid KW, FD Mairinger (2022): Signaling pathways linked to activity of cancer-associated fibroblasts lead to cancer progression and increased tumor cell motility in malignant pleural mesothelioma. Oncol Res Treat. Volume 45 (Supplement 3) P416. Posterpräsentation auf dem 35. Deutschen Krebskongress.

4) Kraus F, Nilius G, Bölükbas S, Stöver I, Koziorowski A, Grabellus F, Christoph DC (2022): Clinical and pathological features and prognosis of non-small cell lung cancer (NSCLC) patients with adenocarcinomas without TTF1 and Napsin A expression. Oncol Res Treat. Volume 45 (Supplement 3), P433. Posterpräsentation auf dem 35. Deutschen Krebskongress.

5) Christoph D, Girard N, Smit H.J.M, Sibille A, Mcdonald F, Mornex F, Garassino MC, Filippi AR, Peters S, Field JK, Drageset Haakensen V, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A; Licour M, Garrido P, Fietkau R (2022): Pacific-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy. Oncol Res Treat. Volume 45 (Supplement 3), P256. Posterpräsentation auf dem 35. Deutschen Krebskongress.

6) Gröschel A, Passlick B, Stuschke M., Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph D, Bernhardt C, Reiser M, M.-O. Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2022): Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany – AIO-TRK-0315. Oncol Res Treat. Volume 45 (Supplement 3), P135. Posterpräsentation auf dem 35. Deutscher Krebskongress.

7) Zeuschner P, Hölters S, Stöckle M, Seliger B, Müller A, Bachmann HS, Grünwald V, Christoph DC, Stenzl A, Grimm M-O, Brüning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-Rüd I, Stähler M, Junker K (2022): Thrombospondin-2 and LDH: potential predictive biomarkers for the treatment of metastatic renal cell carcinoma with everolimus after one VEGF-targeted therapy (MARC-2 study). Oncol Res Treat. Volume 45 (Supplement 3), P128. Posterpräsentation auf dem 35. Deutschen Krebskongress.

8) Eberhardt W, Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Ludwig P, Hipper A, Chiabudini M, Spring L, Jänicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Sebastian M, Griesinger F, Thomas M (2022): V899 Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Real-World Evidence zu NSCLC Patienten behandelt mit Radiochemotherapie in Deutschland – AIO-TRK-0315. Oncol Res Treat. Volume 45 (Supplement 2), V899. Vortrag auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

9) Sebastian M, Reck M, Fischer R, Christoph DC, Bernhardt C, von der Heyde E, Nusch A, Ludwig P, Hipper A, Hanselmann J, Medinger T, Binninger A, Jänicke M, Christopoulos P, Elender C, Bethge A, Seese B, Gauler T, Waller CF (2022): P327 Erste Real-World Outcome-Daten von Patienten mit SCLC in Deutschland – Daten aus der Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315). Oncol Res Treat. Volume 45 (Supplement 2), P327. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

10) Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Grah C, Hoffknecht P, Ludwig P, Hipper A, Chiabudini M, Spring L, Jänicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Nusch A, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2022): Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-World Evidence of NSCLC Stage I, II and III in Germany – AIO-TRK-0315. Zentralblatt für Chirurgie 147 (S01). V-130. Vortrag auf der Jahrestagung der DGT.

11) Sebastian M, Reck M, Fischer RN, Christoph DC, Bernhardt C, von der Heyde E, Nusch A, Ludwig P, Hipper A, Hanselmann J, Medinger T, Binninger A, Jänicke M, Christopoulos P, Elender C, Bethge A, Seese B, Gauler TC, Waller C (2022). First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315). Ann Oncol. 33 (S7), P1542. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

12) Kuon JB, Blasi M, Kokowsk K, Faehling M, Schuette W, Christoph DC, Kimmich M, Engel-Riedel W, Fischer J, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum Bueschenfelde C, Griesinger F, Schneider M, Behnisch R, Stenzinger A, Christopoulos P, Thomas M (2022): DURATION – a phase II randomized trial in older / frail patients (pts) with advanced non-small cell lung cancer (NSCLC) comparing chemotherapy (CTX, 4 cycles) with CTX (2 cycles) and consecutive durvalumab (D): Top-line early efficacy endpoints. Ann Oncol. 33 (S7), P1021. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

13) Eberhardt WEE, Passlick B Stuschke M, Groeschel A, Christopoulos P Reck M, Ludwig P, Hipper A, Chiabudini M, Spring L, Jänicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Sebastian M, Griesinger F, Thomas M (2022): Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315. Ann Oncol. 33 (S7), P963. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

14) Stuschke M, Eberhardt W, Passlick B, Groeschel A, Christopoulos P, Reck M, Grah C, Hoffknecht P, Ludwig P, Hipper A, Chiabudini M, Spring L, Jaenicke M, Andres-Pons A, Christoph DC, Bernhardt C, Reiser M, Nusch A, Sebastian M, Griesinger F, Thomas M (2022): EP05.01-030 CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany – AIO-TRK-0315. J Thorac Oncol. Volume 17, Issue 9, Supplement. EP05.01. Posterpräsentation auf der World Conference on Lung Cancer 2022.

2021
1) Kuon J, Blasi M, Kokowski K, Faehling M, Schütte W, Christoph DC, Kimmich M, Engel-Riedel W, Fischer JR, Lehmann M, Ulmer M, Schuett P, Moosmann N, Meyer zum Büschenfelde C, Griesinger F, Fischer von Weikersthal L, Schmidt B, Gleiber W, Kirchen H, Werke M, Rückert A, Fröhling K-P, Schmidtke-Schrezenmeier G, Moulin J-C, Denzlinger C, Bösche M, Grohé C, Bernhard H, Maintz C, Heinrich K, Kern J, Schneider MA, Krisam J, Sternsinger A, Thomas M (2021): Durvalumab in frail and older patients with stage IV non-small cell lung cancer: the randomized phase II DURATION trial. J Cancer Res Clin Oncol. Volume 44 (Supplement 2), ep641. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

2) Galuba JM, Imke S, Koziorowski A, Bölükbas S, Nilius G, Christoph DC (2021): Efficacy and safety of simultaneously performed radiotherapy in patients with small-cell lung cancer undergoing Atezolizumab treatment. Oncol Res Treat. Volume 44 (Supplement 2), ep577. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

3) Kraus F, Nilius G, Bölükbas S, Stöver I, Koziorowski A, Grabellus F, Christoph D (2021): Clinical and pathological features and prognosis of non-small cell lung cancer (NSCLC) patients with adenocarcinomas without TTF1 and Napsin A expression. Oncol Res Treat. Volume 44 (Supplement 2), ep573. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO und SGHSSH.

4) Shah R, Klotz LV, Christoph DC, Ried M, Wehler T, Reck M, Wesseler C, Bethge A, de Wit M, Hoffknecht P, Jürgens J, Kopp H-G, Hackanson B, Waller CF, Reinmuth N, Schneider MA, Krisam J, Christopoulos P, Eichhorn ME, Thomas M (2021): Nivolumab with chemotherapy in pleural mesothelioma after surgery – NICITA. Oncol Res Treat.Volume 44 (Supplement 2), ep253. Posterpräsentation auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

5) Christoph DC, Girard N, Smit HJM, Sibille A, McDonald F, Mornex F, Garassino MC, Filippi AR, Peters S, Field JK, Drageset Haakensen V, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A, Licour M, Garrido P, Fietkau R (2021): Pacific-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with Durvalumab after chemoradiotherapy. Oncol Res Treat.Volume 44 (Supplement 2), V495. Vortrag auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

6) Eberhardt WEE, Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, CRISP Registry Group (2021): Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC Stage II and III in Germany – AIO-TRK-0315: J Cancer Res Clin Oncol. Volume 44 (Supplement 2), V288. Vortrag auf der Jahrestagung der DGHO, OeGHO, und SGHSSH.

7) Passlick B, Stuschke M, Gröschel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph D, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt W (2021): Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany – AIO-TRK-0315. Zentralblatt für Chirurgie 146 (S01). V-122. Vortrag auf der Jahrestagung of the DGT.

8) Kraus F, Nilius G, Bölükbas S, Stöver I, Koziorowski A, Grabellus F, Christoph DC (2021): Clinical and pathological features and prognosis of nonsmall cell lung cancer (NSCLC) patients with adenocarcinomas without TTF1 and Napsin A expression. Ann Oncol. 32 (S5), P1812. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

9) Galuba JM, Stöver I, Koziorowski A, Bölükbas S, Nilius G, Christoph DC (2021): Safety of simultaneously performed radiotherapy in patients with small cell lung cancer undergoing atezolizumab treatment. Ann Oncol. 32 (S5), P1652. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

10) Gröschel A, Passlick B, Stuschke M, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt WEE (2021): Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): First real-world evidence of NSCLC stage II and III in Germany – AIO-TRK-0315. Ann Oncol. 32 (S5), P1162. Posterpräsentation auf der Jahrestagung der European Society of Medical Oncology.

11) Girard N, Smit HJM, Sibille A, McDonald F, Mornex F, Garassino MCC, Filippi AR, Peters S, Field JK, Christoph DC, Fietkau R, Haakensen VD, Bar J, Chouaid C, Bray V, Kao S, Sawyer W, Allen A, Licour M, Garrido P (2021): PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Ann Oncol. 32 (S5), MO1171. Mini-Vortrag auf der Jahrestagung der European Society of Medical Oncology.

12) Galuba J, Stöver I, Koziorowski A, Bölükbas S, Nilius G, Christoph D (2021): Safety of Simultaneously Performed Radiotherapy in Patients With Small-Cell Lung Cancer Undergoing Atezolizumab Treatment. J Thorac Oncol. Volume 16, Issue 10, Supplement 1. P63.10. Posterpräsentation auf der World Conference on Lung Cancer 2021.

13) Kraus F, Nilius G, Bölükbas S, Stöver I, Koziorowski A, Grabellus F, Christoph D (2021): Pathological Features & Prognosis of NSCLC Patients With Enteric Adenocarcinomas Without Expression of TTF-1 and Napsin A. J Thorac Oncol. Volume 16, Issue 10, Supplement 1. P56.04. Posterpräsentation auf der World Conference on Lung Cancer 2021.

14) Stuschke M, Passlick B, Gröschel A, Christopoulos P, Reck M, Grah C, Groth A, Hipper A, Chiabudini M, Fleitz A, Jänicke M, Spring L, Christoph DC, Bernhardt C, Reiser M, Zahn M-O, Sebastian M, Griesinger F, Thomas M, Eberhardt WE (2021): Klinische Plattform zur Erforschung molekularer Testung, Behandlung und Krankheitsverlauf von Patienten mit Lungenkrebs (CRISP): Erste Real-World Evidence zu NSCLC Stadium II und III in Deutschland – AIO-TRK-0315 (#175). Strahlentherapie und Onkologie Volume 197, supplement issue 1. VS01-2. Vortrag auf der Jahrestagung der DEGRO.

15) Christoph DC, Ferdinandus J, Metzenmacher M, Kessler P, Umutlu L, Aigner C, Kambartel K-O, Grünwald V, Eberhardt WEE, Fendler WP, Herrmann K, Faehling M (2021). Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapy. Journal of Clinical Oncology 39:15 (supplement) 9050-9050. Posterdiskussion auf der Jahrestagung der American Society of Clinical Oncology.

16) McDonald F, Mornex F, Garassino MC, Filippi AR, Christoph D, Haakensen VD, Agbarya A, Van den Heuvel M, Vercauter P, Chouaid C, Pichon E, Siva S, Steinbusch L, Peretz I, Solomon B, Decoster L, Sawyer W, Allen A, Licour M, Girard N (2021): PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. J Thorac Oncol. Volume 16, Issue 4, Supplement 1. MO79. Mini-Vortrag auf der European Lung Cancer Conference 2021.